Hironori Uematsu1, Kazuto Yamashita1, Susumu Kunisawa1, Kiyohide Fushimi2, Yuichi Imanaka3. 1. Department of Healthcare Economics and Quality Management, Graduate School of Medicine, Kyoto University, Kyoto City, Kyoto, Japan. 2. Department of Health Policy and Informatics, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan. 3. Department of Healthcare Economics and Quality Management, Graduate School of Medicine, Kyoto University, Kyoto City, Kyoto, Japan. Electronic address: imanaka-y@umin.net.
Abstract
BACKGROUND: The quantitative effect of multidrug-resistant bacterial infections on real-world health care resources is not clear. This study aimed to estimate the burden of methicillin-resistant Staphylococcus aureus (MRSA) infections in pneumonia inpatients in Japan. METHODS: Using a nationwide administrative claims database, we analyzed pneumonia patients who had been hospitalized in 1,063 acute care hospitals. Patients who received anti-MRSA drugs were categorized into an anti-MRSA drug group, and the remaining patients comprised the control group. We estimated the burden of length of stay, in-hospital mortality, total antibiotic agent costs, and total hospitalization costs. Risk adjustments were conducted using propensity score matching. RESULTS: The study sample comprised 634 patients administered anti-MRSA drugs and 87,427 control patients. In propensity score-matching analysis (1 to 1), the median length of stay, antibiotic costs, and hospitalization costs of the anti-MRSA drug group were significantly higher than those of the control group (21 days vs 14 days [P < .001], $756 vs $172 [P < .001] and $8,741 vs $5,063 [P < .001], respectively); the attributable excess of these indicators were 9.0 ± 1.6 days, $1,044 ± $101, and $5,548 ± $580, respectively. CONCLUSIONS: These findings may serve as a reference to support further research on multidrug-resistant bacterial infections and eventually inform policy formulation. Copyright Â
BACKGROUND: The quantitative effect of multidrug-resistant bacterial infections on real-world health care resources is not clear. This study aimed to estimate the burden of methicillin-resistant Staphylococcus aureus (MRSA) infections in pneumonia inpatients in Japan. METHODS: Using a nationwide administrative claims database, we analyzed pneumoniapatients who had been hospitalized in 1,063 acute care hospitals. Patients who received anti-MRSA drugs were categorized into an anti-MRSA drug group, and the remaining patients comprised the control group. We estimated the burden of length of stay, in-hospital mortality, total antibiotic agent costs, and total hospitalization costs. Risk adjustments were conducted using propensity score matching. RESULTS: The study sample comprised 634 patients administered anti-MRSA drugs and 87,427 control patients. In propensity score-matching analysis (1 to 1), the median length of stay, antibiotic costs, and hospitalization costs of the anti-MRSA drug group were significantly higher than those of the control group (21 days vs 14 days [P < .001], $756 vs $172 [P < .001] and $8,741 vs $5,063 [P < .001], respectively); the attributable excess of these indicators were 9.0 ± 1.6 days, $1,044 ± $101, and $5,548 ± $580, respectively. CONCLUSIONS: These findings may serve as a reference to support further research on multidrug-resistant bacterial infections and eventually inform policy formulation. Copyright Â
Authors: Alan Hibbitts; Ainhoa Lucía; Inés Serrano-Sevilla; Laura De Matteis; Michael McArthur; Jesús M de la Fuente; José A Aínsa; Fabrice Navarro Journal: PLoS One Date: 2019-09-03 Impact factor: 3.240
Authors: Ali Al Bshabshe; Martin R P Joseph; Amgad A Awad El-Gied; Abdalla N Fadul; Harish C Chandramoorthy; Mohamed E Hamid Journal: Biomed Res Int Date: 2020-02-18 Impact factor: 3.411